Comparative Pharmacology
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus PRASUGREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus PRASUGREL.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs PRASUGREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, blocking ADP binding and preventing platelet aggregation.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
60 mg orally once daily as a loading dose, then 10 mg orally once daily maintenance
None Documented
None Documented
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Clinical Note
moderatePrasugrel + Tranilast
"Prasugrel may increase the anticoagulant activities of Tranilast."
Clinical Note
moderatePrasugrel + Resveratrol
"Prasugrel may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderatePrasugrel + Nimesulide
"Prasugrel may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderatePrasugrel + Epoprostenol
"Prasugrel may increase the antiplatelet activities of Epoprostenol."
The active metabolite has a terminal elimination half-life of about 7 hours (range 2–15 hours). This corresponds to once-daily dosing. Prasugrel itself is rapidly hydrolyzed and has a half-life of about 2 hours.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Approximately 68% of the dose is excreted in urine as inactive metabolites, and 27% in feces. No significant renal excretion of parent drug.
Category D/X
Category A/B
NSAID / Antiplatelet
Antiplatelet